Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

79.00USD
20 Sep 2018
Change (% chg)

$1.50 (+1.94%)
Prev Close
$77.50
Open
$77.77
Day's High
$79.16
Day's Low
$77.67
Volume
535,885
Avg. Vol
278,613
52-wk High
$79.16
52-wk Low
$47.79

Chart for

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $12,306.34
Shares Outstanding(Mil.): 158.79
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 107.68 32.65
EPS (TTM): -0.34 -- --
ROI: -4.42 1.61 12.72
ROE: -4.56 0.32 14.84

BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73

* SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

26 Apr 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

10 Apr 2018

BRIEF-Seattle Genetics Says CEO Clay Siegall's 2017 Total Compensation Was $8.6 Mln Vs $9.6 Mln In 2016‍​

* SEATTLE GENETICS INC SAYS CEO CLAY B. SIEGALL'S 2017 TOTAL COMPENSATION WAS $8.6 MLN VS $9.6 MLN IN 2016 – SEC FILING‍​‍​ Source text: (https://bit.ly/2GxkWMO) Further company coverage:

04 Apr 2018

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

26 Mar 2018

Competitors

Earnings vs. Estimates